You are here

Jack Cuzick, PhD

Professor of Epidemiology
Queen Mary University of London
Australia and New Zealand Breast Cancer Trials Group
Cancer Research UK
London, United Kingdom

Current Research

  • Seeking to improve risk assessment in high-risk women by identifying protein and gene biomarkers.

  • Analyses of clinical trial specimens including blood, tumor tissue, mammograms and clinical data are conducted to identify biomarkers to improve risk prediction. 

  • The creation of a large biobank of clinical trial specimens ensures an invaluable resource to study breast cancer outcomes and identify risk prediction biomarkers.

Well-designed randomized clinical trials may provide information about prevention strategies and effective treatments for women at risk of, or diagnosed with, breast cancer. A major limitation of clinical trials, however, is that results apply to the trial group as a whole, but not necessarily to each individual woman, because individual responses are influenced by the patient's and the tumor's unique DNA, or genetic profile.

The goal of the BCRF research led by Drs. Cuzick and Forbes is to precisely identify risks for individual women based on protein and gene biomarkers that can predict outcomes for the prevention and treatment of breast cancer. To do this, they created a High Risk Breast Bio-Bank (HRBB) that includes blood, tumor tissue, and mammograms with clinical outcome data and long-term follow-up of individual women in prevention and treatment trials.

In the coming year, Drs. Cuzick and Forbes will continue to add to the HRBB and conduct analyses of clinical outcome data and biomarkers to improve prediction of risks for the trial population. The following ongoing studies will provide new tissue sources for the HRBB:

1) A randomized phase II neoadjuvant trial called ELIMINATE, which is currently open to enrollment;

2) EXPERT is a randomized phase III trial of adjuvant radiation therapy versus observation following breast-conserving surgery and endocrine therapy in patients with molecularly characterized luminal-A early breast cancer.  

3) The pilot study IBIS-III is an International Breast Intervention Study investigating prevention of late recurrence in ER+ breast cancer survivors following 5 years of adjuvant aromatase inhibitor treatment.

Tissue collected from these trials will expand the excellent HRBB resource for future translational research.


Jack Cuzick is a Director of the Wolfson Institute of Preventive Medicine in London. He is also head of the Centre for Cancer Prevention and John Snow Professor of Epidemiology at Queen Mary, University of London. He holds a PhD in Mathematics and has previously worked at Oxford University and Columbia University, New York. His current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening. He is currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. He has worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumors as an indicator of its potential chemopreventive role and also has demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness. He is involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behavior of early prostate cancer. He is a Fellow of the Academy of Medical Sciences, the Royal Statistical Society, the Institute of Mathematical Statistics and an Honorary Fellow of the Royal College of Physicians. In 2007, he was chosen by Thompson Scientific as one of the twelve hottest researchers in all of science. He was awarded the AACR Cancer Prevention Prize in 2012. He is the author of 520 peer-reviewed papers and has published in all the major medical journals.

BCRF Investigator Since


Donor Recognition

The Delta Air Lines Award

Area(s) of Focus